Polycystic kidney disease (PKD) is a common cause of renal failure with few effective treatments. INPP5E is an inositol polyphosphate 5-phosphatase that dephosphorylates phosphoinositide 3-kinase (PI3K)-generated PI(3,4,5)P 3 and is mutated in ciliopathy syndromes. Germline Inpp5e deletion is embryonically lethal, attributed to cilia stability defects, and is associated with polycystic kidneys. However, the molecular mechanisms responsible for PKD development upon Inpp5e loss remain unknown. Here, we show conditional inactivation of Inpp5e in mouse kidney epithelium results in severe PKD and renal failure, associated with a partial reduction in cilia number and hyperactivation of PI3K/Akt and downstream mammalian target of rapamycin complex 1 (mTORC1) signaling. Treatment with an mTORC1 inhibitor improved kidney morphology and function, but did not affect cilia number or length. Therefore, we identify Inpp5e as an essential inhibitor of the PI3K/Akt/mTORC1 signaling axis in renal epithelial cells, and demonstrate a critical role for Inpp5e-dependent mTORC1 regulation in PKD suppression.
Introduction
Polycystic kidney disease (PKD) results in the progressive dilation of renal tubules, manifesting as kidney enlargement over decades, often leading to renal failure. PKD develops as a consequence of abnormal renal epithelial cell proliferation and fluid secretion, leading to the formation of enlarged, detached and fluid filled cysts. PKD is most commonly associated with autosomal dominant PKD (ADPKD) or autosomal recessive PKD, caused by mutations in PKD1/PKD2 (encoding polycystin-1 and polycycstin-2) or PKHD1 (encoding fibrocystin), respectively (1) (2) (3) . PKD is also a feature of ciliopathy syndromes, an emerging group of genetic diseases caused by cilia dysfunction, characterized by additional developmental abnormalities including retinal degeneration and polydactyly (4) (5) (6) .
The mammalian target of rapamycin (mTOR) is a serine/ threonine kinase that forms two discrete complexes, mTORC1 and mTORC2, which are central to regulation of cell proliferation, metabolism and survival (7) . mTORC1 is activated downstream of a number of inputs, including inactivation of the tumor suppressors tuberous sclerosis 1 (TSC1) and 2 (TSC2), increased nutrient availability, activation of phosphoinositide 3-kinase (PI3K)/Akt signaling (7) or loss of polycystin-1 function, which protects TSC2 from inactivation (8) . In ciliated cultured cells subjected to flow, complete loss of cilia-mediated mechano-sensation activates mTORC1 (9) . Tsc1/2 and Pkd1 rodent mutants develop renal cysts with evidence of mTORC1 activation (10) (11) (12) , as do some mouse mutants harboring loss of function of ciliary proteins (9, (13) (14) (15) . However, the mechanisms by which cilia defects may promote mTORC1 activation in vivo are not well established.
Growth factor stimulation activates class I PI3K, which phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P 2 ) at the D-3 position to transiently produce phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P 3 ) which is converted to phosphatidylinositol 3,4-bisphosphate (PI(3,4)P 2 ) by inositol polyphosphate 5-phosphatases on the inner leaflet of the plasma membrane (16) (17) (18) . Both PI(3,4,5)P 3 and PI(3,4)P 2 are required for maximal activation of the serine/threonine kinase, Akt (19) (20) (21) (22) , and once activated by phosphorylation at two sites Ser 473 and Thr
308
, Akt promotes mTORC1 activity via inhibitory phosphorylation of TSC2 (16, 23) . PTEN hydrolyses PI(3,4,5)P 3 to form PI(4,5)P 2 and potently terminates PI3K/Akt/mTOR signaling in many cell types (24) . However, surprisingly, kidney-specific deletion of the tumor suppressor Pten, does not produce a cystic renal phenotype or substantial mTORC1 activation (25, 26) . The absence of a kidney phenotype upon Pten deletion suggests regulatory inputs besides PI3K/Akt are dominant in controlling mTORC1 activity in kidney epithelium, or alternatively, that other mechanisms are primarily responsible for degrading PI(3,4,5)P 3 signals in renal epithelial cells. Therefore, whether PI3K/Akt signaling represents an important physiological regulator of mTORC1 in PKD development remains unclear.
An alternate pathway for the regulation of PI(3,4,5)P 3 signaling is mediated by the inositol polyphosphate 5-phosphatase (5-phosphatase) enzyme family, many members of which hydrolyse the 5-position phosphate from the inositol head group of PI(3,4,5)P 3 to yield PI(3,4)P 2 (18) . Many studies have reported the 5-phosphatases SHIP1, SHIP2, SKIP, INPP5E and PIPP degrade PI(3,4,5)P 3 and thereby suppress Akt signaling, despite potentially increasing the cellular levels of PI(3,4)P 2 (18, (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . Several 5-phosphatase family members are expressed in the kidney and regulate its function, but only INPP5E is implicated in PKD (18, 39, 40) . Inpp5e knockout mice exhibit embryonic/perinatal lethality with features that resemble human ciliopathy syndromes including exencephaly, polydactyly and PKD associated with partial cilia loss in cysts. Cilia stability defects have been identified in mouse embryonic fibroblasts that lack Inpp5e (40) . As mutations in INPP5E have been identified in human ciliopathies; Joubert syndrome and related disorders (JSRD) and mental retardation, truncal obesity, retinal dystrophy and micropenis (MORM) (39) (40) (41) , it has been predicted that many of the Inpp5e-null phenotypes may relate to cilia defects. We and others have shown that INPP5E dephosphorylates PI(3,4,5)P 3 , at the D-5 position to produce PI(3,4)P 2 (27) (28) (29) (30) and inhibits PI3K/ Akt signaling (42, 43) in cultured cells. However, whether deregulation of this signaling pathway contributes to PKD is unclear, and the molecular basis of PKD arising from Inpp5e inactivation remains to be determined, and has been challenging to investigate due to the embryonic/perinatal lethality of Inpp5e knockout mice.
Here, we inactivated Inpp5e specifically in renal epithelium to determine the cell-autonomous roles this 5- ;Ksp-Cre kidneys exhibited significantly increased PI3K/Akt/mTORC1 signaling in cystic renal epithelium and also in isolated primary renal epithelial cells (pRECs). Despite only a partial decrease in the number of ciliated cells upon Inpp5e ablation, mTORC1 signaling was increased and furthermore, in cultured cells, increased mTORC1 activation was observed in both ciliated and non-ciliated cells. Treatment of Inpp5e fl/fl ;Ksp-Cre mice with a pharmacological mTORC1 inhibitor improved kidney architecture and function, with evidence of mTORC1 signaling suppression, without affecting cilia number. Therefore, we establish a critical role for PI3K/ Akt-dependent mTORC1 activation in PKD pathogenesis and identify Inpp5e as an essential inhibitor of this signaling axis in renal epithelium.
Results
Inpp5e is essential for renal epithelial cell function and maintenance of renal architecture
Renal epithelial cells are the proposed cell of origin of renal cysts in PKD and interestingly neither constitutive nor inducible murine renal epithelial cell-specific ablation of Pten induces a cystic phenotype (26, 44) . This may relate to the localized expression of PTEN predominantly to proximal renal tubules (45, 46) and/or that other phosphoinositide phosphatases may regulate Akt/mTORC1 signaling in distal tubules and collecting ducts, the latter of which is the major site for cyst development in PKD (47) (48) (49) (50) . To determine the relative levels of Inpp5e compared with Pten in renal epithelium, Inpp5e and Pten mRNA levels were determined by droplet digital polymerase chain reaction (PCR) using pRECs isolated from P16 wild-type kidneys. pRECS were isolated using a method adapted from a previously published study (51) , and include epithelial cells from all tubule segments. Notably, Inpp5e was expressed at 3-fold higher levels than Pten, consistent with the contention that Inpp5e is a major regulator of PI3K/Akt signaling in renal epithelial cells (Supplementary Material, Fig. S1a ). The protein expression of both Pten and Inpp5e in isolated pRECs was also confirmed by immunoblot analysis (Supplementary Material, Fig. S1b) , however it should be noted that due to different antibodies used to detect each protein, this analysis does not demonstrate relative expression, but is further evidence that Inpp5e protein is expressed in renal epithelial cells. To investigate Inpp5e function in vivo, we generated mouse mutants with a targeted Inpp5e allele possessing LoxP sites flanking exons 2-6 (Inpp5e ) embryos that died at $E18.5 and displayed a ciliopathy phenotype including polydactyly, exencephaly and polycystic kidneys (data not shown), consistent with the only reported Inpp5e-null phenotype, which targeted exons 7-8 (40) .
To define the cell-autonomous roles of Inpp5e in the kidney, the 5-phosphatase was inactivated only in renal epithelial cells by crossing Inpp5e fl/fl mice with Tg(Cdh16-cre)91Igr (Ksp1.3-Cre, referred to herein as Ksp-Cre) mice (52) . The Ksp-Cre transgene contains 1341bp of the 5 0 -flanking region of the Ksp-Cadherin (Cdh16) gene that drives expression of Cre during kidney development as early as E11.5 in the mesonephros, then in developing metanephros, in epithelial cells of the branching ureteric bud and developing tubules from E12.5. In adult mice, Ksp-Cre is expressed in renal epithelial cells, most highly in the loop of Henle, distal tubule and collecting duct epithelium, with low ;Ksp-Cre littermates, and kidneys were normal in appearance at birth (Fig. 1a) ;Ksp-Cre kidneys at P1, however, by P7, focal cysts were observed in both cortical and medullary regions, and at P14, cysts were numerous and large (Fig. 1e) . By P21, cysts were very large and represented the majority of the renal volume, with little normal parenchyma remaining ( (Fig. 1g, bottom left tile, open arrows), however, large cysts arose from the distal tubule/ loop of Henle and collecting duct epithelium (Fig. 1g , bottom center and bottom right panels).
The role of cilia in the development of PKD is complex and not well understood. In mice, perinatal cilia ablation during renal development results in severe cystic disease, however, later post-natal cilia loss fails to induce PKD unless the kidney is subjected to injury (13, 56, 57) suggesting that both temporal and contextual regulation of cilia influences disease pathogenesis. Furthermore, in some PKD mouse models, cilia depletion slows, rather than accelerates, disease progression (58) . Despite this, loss of cilia is a hallmark feature of PKD, but whether defective cilia-mediated mechano-sensation alone is sufficient to drive cystogenesis is unclear (57, 59) . Growing evidence suggests that cilia dysfunction is not the sole cause of PKD and that the extraciliary functions of cystic proteins also play a critical role in disease pathogenesis (59, 60) . We examined whether renal cyst development as a consequence of Inpp5e loss specifically in renal epithelial cells was associated with a reduction in cilia number ;Ksp-Cre kidneys displayed a partial reduction in cilia number in the distal tubule/loop of Henle epithelium and collecting duct epithelium to 36.8% and 40.5% of cells, respectively, but no change in proximal tubules ( Fig. 2a-d) , a site at which the Ksp-Cre transgene is minimally active (52, 53) . The partial reduction in cilia number is consistent with the known role for INPP5E in regulating cilia stability (39, 40) .
Inpp5e regulates PI3K/Akt and downstream mTORC1 signaling in the kidney
The mTOR signaling pathway integrates growth factor receptor signaling with nutrient availability, to control cell size and metabolism, and also plays a role in the pathogenesis of PKD. mTORC1 promotes protein translation and cell proliferation, and is co-ordinately regulated by amino acid availability, energy stress and mitogenic signals (7) . Notably, genetic mutations in the mTORC1 inhibitory proteins, TSC1 and TSC2, leads to renal cysts in humans and rodent models (12, 26, (61) (62) (63) (64) . PI3K/Akt signaling provides a major mitogen-dependent regulatory input to the mTORC1 pathway. PI3K-generated PI(3,4,5)P 3 activates Akt via membrane recruitment and thereby enables its phosphorylation by PDK1 and mTORC2 at Thr 308 and Ser
473
, respectively (65) (66) (67) (68) . Activated Akt in turn phosphorylates many effectors including inhibitory phosphorylation of TSC2, and thereby promotes mTORC1 activity (16) . However, deletion of Pten, a potent negative regulator of Akt signaling, in renal epithelium has limited effects on mTORC1 activity and does not induce cyst formation (26, 44) . No other murine model of a known PI3K/Akt signaling regulator in renal epithelium has been reported and therefore, it is unclear if PI3K/Akt is a bona fide activator of mTORC1 in renal epithelium and if dysregulation of this signaling axis contributes to PKD pathogenesis. To reveal mTORC1 activation, the phosphorylation of key mTORC1 effectors was assessed. 4EBP1 sequesters eIF4E and prevents its complex formation that is required for translation initiation. mTORC1 phosphorylates 4EBP1, leading to release of eIF4E and enabling capdependent mRNA translation (7) . mTORC1 phosphorylation of p70-S6K is activating and promotes phosphorylation of many substrates, including S6RP, which promotes proliferation (70 Fig. S2 ) and may occur as a consequence of increased mTORC1 activity leading to increased protein translation.
Studies using purified recombinant INPP5E have demonstrated this 5-phosphatase is the most active family member in degrading PI(3,4,5)P 3 to generate PI(3,4)P 2 (27) . To assess whether INPP5E regulates the total cellular levels of these lipids in renal epithelial cells, the total cellular PI(3,4,5)P 3 mass was assessed using an enzyme-linked immunosorbent assay (ELISA)-based mass assay and was increased $2-fold in primary Inpp5e-deficient pRECs relative to wild-type cells (Fig. 3e) . PI(3,4)P 2 signals were reduced in Inpp5e-deficient pRECs that was approaching statistical significance (Fig. 3f) . Therefore in the absence of Inpp5e, PI(3,4,5)P 3 signals are increased in renal epithelial cells. Overall, these data suggest that Inpp5e inhibits PI3K/Akt/ mTORC1 signaling in renal epithelium and that Inpp5e ablation leads to hyperactivation of this signaling axis. Pkd1 mutant mice display mTORC1 activation, however, only in a subset of renal cysts (12) and heterogeneous p-S6RP staining is reported in human ADPKD cysts (71 Material, Fig. S4 ). Akt recruitment to the apical membrane of cells is critical for its activation and downstream signaling, including cytoskeletal remodeling (16, 73) . Notably, p-Akt ;Ksp-Cre kidneys; at P7 many epithelial cells showed strong positive cytoplasmic staining, and by P21, most kidney epithelial cells lining dilated cysts were strongly immunoreactive (Fig. 4b, arrowheads) (Fig. 5a i and a ii) . Commercially available antibodies to INPP5E failed to show a distinct signal in pRECs or other cell types by immunofluorescence (not shown). Therefore, HA-tagged Inpp5e (HA-Inpp5e) was expressed in pRECs and its co-localization with the acetylated a-tubulin-positive axoneme was observed in ciliated cells, consistent with other reports (39, 40, 74) (Fig. 5b , upper panels, arrowhead). We also examined non-ciliated renal epithelial cells, as these cells are also present in renal tubules (75) (76) (77) (78) . In non-ciliated pRECs HA-Inpp5e localized to the cytosol and was enriched at the plasma membrane (Fig. 5b , lower panels, arrowheads), consistent with its previously described location in nonciliated cells (79) . We show here that the total PI(3,4,5)P 3 mass was increased in pRECs derived from Inpp5e fl/fl ;Ksp-Cre kidneys. Several studies have used PI(3,4,5)P 3 specific antibodies to successfully localize this phosphoinositide to the plasma membrane (80-82), however, its recent use in an attempt to detect PI(3,4,5)P 3 in ciliated cells was negative, potentially due to technical reasons (83) . Therefore, here, PI(3,4,5)P 3 antibody staining of the non-ciliated cell population was performed in pRECs, revealing increased plasma membrane staining in Inpp5e-deficient pRECs, relative to wild-type controls (Fig. 5c , zoomed lower panels, arrowheads). Akt and mTORC1 signaling converge on the proline rich Akt substrate of 40 kDa (PRAS40) which is a substrate for both kinases and an inhibitory component of mTORC1 (84) . The phosphorylation of PRAS40 by Akt and mTORC1 itself relieves its inhibitory association with mTORC1, thereby promoting mTORC1 signaling (84) . As a marker of Akt activation, we examined the phosphorylation of PRAS40 by Akt (p-PRAS40 T246 ) which was increased in Inpp5e-deficient cells at the plasma membrane (Fig. 5d, zoomed lower -positive cells was increased with Inpp5e ablation (Fig. 5e ii) . When further analyzed, we found that p-S6RP S234/236 -positive cells were increased in both the ciliated and non-ciliated population of Inpp5e-deficient pRECs, relative to wild-type cells (Fig. 5f i-iii) . Collectively, these data reveal that Inpp5e ablation in renal epithelial cells leads to increased mTORC1 signaling in both ciliated and non-ciliated cells. ;Ksp-Cre mice were treated daily from P8 with Everolimus or placebo control for 13 days at a dose of 4 mg/kg/day and were killed and examined at P21. Mice were too immature prior to P8 for mTORC1 inhibitor treatment, so at the commencement of Everolimus treatment, multiple small renal cysts were already apparent. Notably, Inpp5e fl/fl ;Ksp-Cre mice receiving Everolimus displayed significantly reduced kidney size and weight ( Fig. 6a  and 6c ), associated with a 50% improvement in renal function, demonstrated by reduced serum urea compared with placebotreated controls (Fig. 6d) . Interestingly, Hematoxylin and Eosin (H&E) staining revealed that the reduction in kidney volume in response to Everolimus treatment was due to a decrease in cyst size rather than number (Fig. 6b) . Everolimus-mediated attenuation of mTORC1 signaling was assessed by examining the phosphorylation of its effectors, 4EBP1 and S6RP, by IHC and phospho-immunoblot analyses. p-S6RP S234/236 was significantly reduced in renal epithelium of Everolimus-treated mice compared with placebo-treated controls (Fig. 6e, upper panels) ; however, p-4EBP1 T37/46 was similarly elevated in in the cystic epithelium of both Everolimus and placebo-treated Inpp5e fl/fl ;Ksp-Cre kidneys (Fig. 6e , middle panels). Phospho-immunoblot analysis revealed significantly reduced p-S6RP S234/236 in Everolimus-treated mouse kidneys relative to placebo controls, whereas p-4EBP1 T37/46 levels were unchanged ( Fig. 6f-h) , consistent with the IHC analysis. Our observations are consistent with previous studies reporting that rapamycin-and rapalogue-mediated inhibition of mTORC1 effectively blocks downstream S6K activation but does not efficiently prevent 4EBP1 phosphorylation and inactivation (86) . In Tsc1/2 mutants, chronic activation of mTORC1 signaling negatively feeds back to inhibit Akt activation via a variety of mechanisms (87-92). Pharmacological inhibition of mTORC1 relieves this negative feedback and promotes Akt activation in various rodent models (90, (93) (94) (95) (96) (97) (98) . We therefore assessed Akt phosphorylation in Everolimus-treated Inpp5e fl/fl ;Ksp-Cre kidneys. IHC revealed more widespread p-Akt S473 staining in epithelia lining cysts in Everolimus-treated kidneys compared with placebo controls (Fig. 6e, bottom panels) . Phospho-immunoblot analysis showed a trend for increased p-Akt T308 and p-Akt S473 in
Inhibition of mTORC1 signaling attenuates PKD in
Everolimus treated Inpp5e fl/fl ;Ksp-Cre kidneys compared with controls, although this was not statistically significant (Fig. 6f, 6i and 6j). We also analyzed renal cilia in Everolimus and placebotreated ;Ksp-Cre kidney tubules and isolated renal epithelial cells and mTORC1 activation was observed in both ciliated and non-ciliated cell populations. Collectively, these studies identify PI3K/Akt signaling as an important activator of mTORC1 in PKD, and suggest that molecular regulators or pharmacological inhibitors of PI3K/Akt may suppress mTORC1 driven cyst development. Furthermore, Pten ablation in renal epithelium fails to induce renal cyst development in vivo (25, 26) , in contrast to the dramatic cystic phenotype observed with renal epithelial cell Inpp5e ablation as shown here. Therefore, we conclude that in renal epithelium, Inpp5e rather than Pten acts as the dominant suppressor of PI3K/Akt signaling.
Inpp5e is a negative regulator of PI3K/Akt/mTORC1 signaling in cultured cells (30) , however, the physiological relevance of Inpp5e as an in vivo regulator of this signaling axis has been unclear. Here, we detected increased p-Akt S473 in the epithelial cells of developing cysts in Inpp5e fl/fl ;Ksp-Cre mouse kidneys, and increased p-Akt S473 and p-Akt T308 in kidney lysates, consistent with PI3K hyperactivation. We observed concomitant activation of mTORC1 signaling components in the epithelium of developing cysts and kidney lysates, as shown by increased p- . Therefore, PI3K/Akt activation is apparent with similar spatio-temporal dynamics to mTORC1 activation, suggesting that Akt signaling drives mTORC1 activation in this model. Genetic mutation/deletion of genes that regulate mTORC1 signaling give rise to PKD in both animals and humans (12, 26, (61) (62) (63) (64) 99) , however, until now PI3K/ Akt activation as a molecular driver of mTORC1 in this context has not been reported. Inpp5e D/D knockout mice (40) and Inpp5e fl/ fl ;Ksp-Cre mice described here, display PKD. Although some Inpp5e D/D mouse phenotypes may be attributed to defective cilia (40), we provide evidence here to suggest PKD resulting from renal epithelial cell-specific Inpp5e inactivation is, at least in part, driven by unrestrained PI3K/Akt/mTORC1 signaling, as the phenotype is partially rescued by mTORC1 inhibition without affecting renal cilia. Furthermore, mTORC1 activation is observed in both ciliated and non-ciliated Inpp5e-deficient pRECs. Akt and downstream mTORC1 activation occurs early in cyst development in Inpp5e fl/ fl ;Ksp-Cre kidneys and progressively increases with disease progression, consistent with the contention that aberrant cell-autonomous activation of Akt as a consequence of Inpp5e loss drives cyst development via the mTORC1 signaling pathway.
Many studies indicate that PI3K/Akt signaling is a major input leading to mTORC1 activation (100); however, evidence that this axis is conserved in kidney epithelium is lacking. Indeed, kidney-specific deletion of Pten in mice does not produce a cystic renal phenotype or robust Akt/mTORC1 activation (25, 26) , despite its well established roles in potently inhibiting PI3K/Akt/ mTORC1 in other cellular systems and tissues (24) . This is possibly a consequence of the effects of other PI(3,4,5)P 3 phosphatases such as INPP5E that, as reported here, are expressed at higher levels in renal epithelial cells compared with PTEN. Furthermore, as shown here, loss of Inpp5e results in increased PI(3,4,5)P 3 signals but no significant change in PI(3,4)P 2 levels, correlating with increased Akt/mTORC1 pathway activation. Therefore, although both PI(3,4,5)P 3 and PI(3,4)P 2 are required for full Akt activation (19) (20) (21) (22) , loss of 5-phosphatases such as Inpp5e can induce hyperactivation of this pathway despite mediating the conversion of PI(3,4,5)P 3 to PI(3,4)P 2 . In populations of renal epithelial cells where PTEN is expressed at low levels, Inpp5e plays a significant role in suppressing PI3K/Akt/mTORC1 signaling.
In vitro studies have defined a role for cilia in restraining mTORC1 signaling, whereby cilia-dependent mechanosensation of fluid flow activates liver kinase B1 to phosphorylate AMPK, which maintains mTORC1 repression independent of Akt (9). However, it is unclear whether depletion of cilia per se activates mTORC1 signaling in vivo. The renal cysts that arise as a consequence of Inpp5e inactivation display partial cilia loss, and isolated renal epithelial cells also display a modest reduction in cilia number. We therefore propose a model whereby loss of Inpp5e leads to a mild reduction of ciliated cells, but in both ciliated and non-ciliated cells, increased PI(3,4,5)P 3 -dependent Akt activation leads to downstream activation of mTORC1 (7) (Fig. 7) . It was beyond the limitations of imaging and affinity of antibodies to identify whether ciliated versus non-ciliated cells within renal tubules or cysts in vivo showed hyperactivation of mTORC1 signaling in Inpp5e fl/fl ;Ksp-Cre mice. However, in pRECs,
where Inpp5e localized to cilia, we observed that both the ciliated and non-ciliated Inpp5e-deficient cell populations displayed increased numbers of p-S6RP S234/236 -positive cells relative to wild-type. Therefore it is interesting to speculate that the cilia localization of Inpp5e serves to suppress localized Akt/ mTORC1 signaling in ciliated cells, and in non-ciliated cells, Inpp5e suppresses plasma membrane localized PI(3,4,5)P 3 -dependent Akt/mTORC1 activation. ;Ksp-Cre mice develop very aggressive, early-onset PKD, with cysts apparent at P1. However, due to the infancy of the mice, Everolimus treatment could not commence until P8, when cysts were already present and mTORC1 signaling was hyperactivated. This is in contrast to other postnatal rodent models of PKD that display milder phenotypes and later onset (101, 102) , features more amenable to pharmacological treatment. In addition, Everolimus treatment did not completely abolish mTORC1 signaling in Inpp5e fl/fl ;Ksp-Cre mouse kidneys. Indeed, rapamycin and rapalogues display variable efficacy in inhibiting the distinct downstream targets of mTORC1.
In particular, 4EBP1 phosphorylation and inactivation is largely resistant to rapamycin, due to the high affinity of mTORC1 for this substrate (86) . Here, Inpp5e fl/fl ;Ksp-Cre kidneys showed attenuation of p-S6RP but not p-4EBP1 signals. In summary, this study demonstrates that loss of Inpp5e specifically in kidney epithelium is sufficient to generate aggressive PKD, providing compelling evidence that hyperactivation of Akt robustly activates mTORC1 signaling in renal epithelial cells, and identifies Inpp5e as a critical inhibitor of PI3K/Akt and downstream mTORC1 signaling in kidney epithelium in vivo. Our results suggest that dual PI3K/mTORC1 inhibition may be of potential therapeutic value for PKD treatment. Immunohistochemistry Formalin fixed and paraffin embedded kidneys were sectioned, dewaxed and rehydrated in sequential xylene, ethanol and water washes. Picrosirius red and H&E staining was performed at ;Ksp-Cre;Z/EG mice, antigen retrieval was performed using epitope retrieval solution, pH 9 (Leica; RE7119) in a pressure cooker for 5 min. Sections were incubated in peroxidase block (Invitrogen; K4011), then blocked using 1% bovine serum albumin (BSA) in 50 mM Tris, 150 mM NaCl, pH 7.5. Sections were incubated with p-Akt S473 antibody (Invitrogen; 700392) diluted in blocking solution 1:500 overnight at 4 C. For all other DAB IHC, sections were subjected to antigen retrieval in 10 mM sodium citrate (pH 6) in a microwave at sub-boiling temperature for For immunofluorescence, sections were subjected to antigen retrieval in 10 mM sodium citrate (pH 6) in a pressure cooker for 4 min. Sections were permeablized in 0.3% Triton X-100 in phosphate buffered saline (PBS) then blocked in 3% BSA in PBS prior to antibody staining. Primary and secondary antibodies and stains were diluted in 3% BSA in PBS and incubated at room temperature. Dilutions and antibodies/stains used are as follows: anti-Pericentrin (Covance; PRB-432C) 1:400, antiacetylated a-Tubulin (Sigma; T7451) 1:1000, anti-uromodulin/ Tamm-Horsfall protein (THP) (MP Cappel; 55140) 1:50, Alexa FluorV R conjugated secondary antibodies (Invitrogen) 1:1000, lectins DBA and LTL (Vector labs; FL-1031/RL-1032 and FL-1321) 1:500 and DAPI (Sigma; 32670) 0.5 lg/ml. Slides were mounted using Fluoromount G (Southern Biotech; 0100-01). Stained specimens were imaged using Olympus Dotslide microscope or a Lecia SP5 5 Channel confocal microscope.
Materials and Methods

Mice and genotyping
Primary renal epithelial cell cultures
pRECs were isolated using a method adapted from Sheridan et al. (51) . Briefly, kidneys from P16 mice were dissected and placed into ice cold PBS with 25 mg/ml Penicillin/Streptomycin (Sigma; P4458). The capsule and ureters were removed and the kidneys were minced using scalpel blades and incubated in 0.2% collagenase A (Sigma; 10103578001) in PBS at 37 C for 30 min with agitation. Following addition of horse serum and brief vortexing, tissue was allowed to settle and the supernatant was collected and centrifuged at 200 g for 7 min. The cell pellet was washed in PBS, centrifuged and resuspended in media and cells were grown on 10 mg/ml collagen (Sigma; C4243) coated tissue culture dishes. Cells were grown in a humidified incubator at 37 C, in DMEM/F12 (Gibco; 11330) containing 100 x ITS-X (Gibco; 51500-056), 20 mg/ml T3 (Sigma; T5516), 1 mg/ml hydrocortisone (Sigma; H0888), 100 mg/ml epidermal growth factor (BD; 35-4001), nystatin suspension (Sigma; N1638), 25 mg/ml Penicillin/Streptomycin and 2 mM L-glutamine (Sigma; 59202C).
Transfections and constructs
The HA-Inpp5e construct used was generated as previously described (28) . Primary kidney epithelial cells were transfected with HA-Inpp5e via electroporation using the Amaxa basic nucleofector kit for primary mammalian epithelial cells (Lonza; VPI-1005) according to the manufacturer's instructions. Transfected cells were plated on ECL cell attachment (Millipore; 08-110)-coated coverslips and incubated for 24 h prior to harvesting.
Fixed cell immunoflourescence
Primary kidney epithelial cells grown on ECL cell attachment (Millipore; 08-110)-coated coverslips were fixed using 4% paraformaldehyde in PBS for 20 min at room temperature. Coverslips were permeablized using methanol for 5 min at À20 C or 0.1% Triton-X in PBS for 15 min, then blocked using 1%
BSA in PBS for 1 h at room temperature prior to antibody staining. Primary antibodies were incubated overnight at 4 C and secondary antibodies were incubated at room temperature for 1 h. Primary and secondary antibodies/stains were diluted in 1% BSA at the following concentrations: anti-acetylated a-tubulin (Sigma; T7451) 1:1000, Alexa FluorV R conjugated secondary antibodies (Invitrogen) 1:1000, anti-HA (Abcam; ab94918) 1:1000, anti-PI(3,4,5)P 3 (Echelon Biosciences; Z-P034) 1:50, anti-p-PRAS40 T246 (Cell Signaling Technology; 2997) 1:500 and DAPI (Sigma; 32670) 0.5 lg/ml. Stained specimens were imaged at 100Â in x and y or x, y and z planes using a Nikon C1 upright confocal microscope.
Immunoblot
Kidneys were cut into pieces and snap frozen prior to homogenization in radioimmunoprecipitation buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM Na 2 VO 4 , 50 mM NaF, 1% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 100 nM calyculin A and protease inhibitor tablet (Roche; 11836153001)). Tissue was homogenized using a QIAGEN rotorstarter homogenizer and centrifuged at 16 100 g to isolate the soluble fraction. Protein concentration of lysates was determined using a DC Protein assay kit (Bio-Rad; 5000111). Lysates were adjusted to a concentration of 2 mg/ml, followed by addition of 2Â reducing buffer (100 mM Tris-HCl, 4% SDS, 0.2% Bromophenol Blue, 20% Glycerol, 200 mM b-mercaptoethanol). Samples were boiled prior to loading in acrylamide gel for SDS-PAGE. Twenty microgram samples were loaded in 7.5%, 10% or 12.5% acrylamide gels and proteins separated at 200 V. Proteins were transferred onto PVDF membranes at 250 mA and membranes were blocked in 5% BSA in TBST (150 mM NaCl, 20 mM Tris-HCl and 0.1% Tween-20 
Droplet digital PCR
RNA was extracted from primary kidney epithelial cells using Isolate II RNA Mini kit (Bioline; BIO-52073) according to the manufacturer's instructions. cDNA synthesis was performed using AffinityScript TM QPCR cDNA Synthesis Kit (Agilent Technologies; 600559). Droplet digital PCR was performed using a Bio-Rad QX100 Droplet Digital PCR system (Bio-Rad, Hercules, CA). Twenty microliter reactions containing 1Â ddPCR EvaGreen Supermix, 1Â Quantitect Primers (QIAGEN) and 8.3 ng/ll cDNA were loaded into the middle wells of a droplet generator cartridge. Seventy microliters of Droplet Generation Oil for EvaGreen (Bio-Rad) was loaded into the lower wells and individual droplets were generated. Forty microliter droplets were transferred to a 96-well PCR plate, sealed and subjected to thermal cycling with 40 PCR cycles of 95 C for 30s, 60 C for 60s.
Following PCR, detection of the completed reactions in individual droplets was detected using a droplet reader. Data were analyzed using QuantaSoft software (Bio-Rad) with the thresholds for detection selected manually based on data acquired from no template controls.
Mass ELISA
pRECs were grown to confluency in 10 cm tissue culture dishes and harvested for PI(3,4)P 2 or PI(3,4,5)P 3 mass ELISA using the PI(3,4)P 2 Mass ELISA kit (Eschelon; K-3800) or PI(3,4,5)P 3 Mass ELISA kit (Echelon; K-2500s), respectively, according to the manufacturer's instructions. Plates were read using a BMG Pherastar FS plate reader.
Everolimus treatment
Male Inpp5e fl/fl ;Ksp-Cre mice were selected for treatment. Mice were treated orally with 4 mg/kg Everolimus (RAD001 20 mg/g emulsion) or placebo (RAD001 0 mg/g emulsion) (Novartis) daily from P8 to P20 and killed for analysis at P21. Mice were monitored three times daily in accordance with Monash University Animal Ethics Committee guidelines.
Cilia and p-S6RP S234/236 analysis
For kidney sections, images were captured on a Lecia SP5 5 Channel confocal microscope using 100Â objective, in x, y and z planes to generate 3D images for cilia analysis. Cilia number was scored as a proportion of cells lining kidney tubules using Imaris or Fiji software, with a minimum of 10 tubules scored for each section. Cilia length was measured using Imaris filament tracer and a minimum of 10 cilia from at least two tubules were scored per sample. All experiments used a minimum of three mice per genotype/treatment. pRECs were imaged on a Nikon C1 upright confocal microscope in x, y and z planes to generate 3D images for cilia analysis. For cilia number analysis, ciliated pRECs were scored from !5 fields captured at 60Â magnification using ImageJ v1.50d software. For cilia/p-S6RP S234/236 analysis, pRECs were imaged by capturing !11 fields at 100Â magnification for each sample, with pREC cultures derived from three separate mice for each genotype Ciliated and non-ciliated p-S6RP cells were scored using ImageJ v1.50d software.
Statistical analyses
Statistical analysis was performed using GraphPad Prism 6 software. Unpaired parametric two tailed t-tests were applied to all data, except for PI(3,4)P 2 and PI(3,4,5)P 3 mass assays, for which an unpaired parametric two tailed t-test with Welch's correction was performed. P-values are indicated using asterisk (*) on graphs and specified in figure legends. Error bars represent standard deviation or standard error of mean and are specified in figure legends.
Supplementary material
Supplementary Material is available at HMG online.
